S&P 500   3,941.48 (-1.53%)
DOW   32,059.85 (-1.54%)
QQQ   312.09 (+0.56%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.67 (+0.71%)
AMZN   100.21 (-0.40%)
TSLA   196.34 (-0.63%)
NVDA   272.70 (+4.09%)
NIO   9.31 (+0.43%)
BABA   84.70 (+1.19%)
AMD   100.52 (+4.78%)
T   18.58 (+0.22%)
F   11.76 (+0.34%)
MU   59.66 (+1.76%)
CGC   1.92 (-2.79%)
GE   91.18 (-1.08%)
DIS   96.87 (+0.34%)
AMC   4.53 (+2.72%)
PFE   40.42 (-0.59%)
PYPL   76.15 (-0.74%)
NFLX   300.91 (-1.60%)
S&P 500   3,941.48 (-1.53%)
DOW   32,059.85 (-1.54%)
QQQ   312.09 (+0.56%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.67 (+0.71%)
AMZN   100.21 (-0.40%)
TSLA   196.34 (-0.63%)
NVDA   272.70 (+4.09%)
NIO   9.31 (+0.43%)
BABA   84.70 (+1.19%)
AMD   100.52 (+4.78%)
T   18.58 (+0.22%)
F   11.76 (+0.34%)
MU   59.66 (+1.76%)
CGC   1.92 (-2.79%)
GE   91.18 (-1.08%)
DIS   96.87 (+0.34%)
AMC   4.53 (+2.72%)
PFE   40.42 (-0.59%)
PYPL   76.15 (-0.74%)
NFLX   300.91 (-1.60%)
S&P 500   3,941.48 (-1.53%)
DOW   32,059.85 (-1.54%)
QQQ   312.09 (+0.56%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.67 (+0.71%)
AMZN   100.21 (-0.40%)
TSLA   196.34 (-0.63%)
NVDA   272.70 (+4.09%)
NIO   9.31 (+0.43%)
BABA   84.70 (+1.19%)
AMD   100.52 (+4.78%)
T   18.58 (+0.22%)
F   11.76 (+0.34%)
MU   59.66 (+1.76%)
CGC   1.92 (-2.79%)
GE   91.18 (-1.08%)
DIS   96.87 (+0.34%)
AMC   4.53 (+2.72%)
PFE   40.42 (-0.59%)
PYPL   76.15 (-0.74%)
NFLX   300.91 (-1.60%)
S&P 500   3,941.48 (-1.53%)
DOW   32,059.85 (-1.54%)
QQQ   312.09 (+0.56%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.67 (+0.71%)
AMZN   100.21 (-0.40%)
TSLA   196.34 (-0.63%)
NVDA   272.70 (+4.09%)
NIO   9.31 (+0.43%)
BABA   84.70 (+1.19%)
AMD   100.52 (+4.78%)
T   18.58 (+0.22%)
F   11.76 (+0.34%)
MU   59.66 (+1.76%)
CGC   1.92 (-2.79%)
GE   91.18 (-1.08%)
DIS   96.87 (+0.34%)
AMC   4.53 (+2.72%)
PFE   40.42 (-0.59%)
PYPL   76.15 (-0.74%)
NFLX   300.91 (-1.60%)
Most-Downgraded Stocks  
NASDAQ:GRPH

Graphite Bio - GRPH Stock Forecast, Price & News

$2.37
+0.04 (+1.72%)
(As of 03/22/2023 03:46 PM ET)
Add
Compare
Today's Range
$2.24
▼
$2.44
50-Day Range
$1.91
▼
$2.69
52-Week Range
$1.59
▼
$6.16
Volume
147,644 shs
Average Volume
317,580 shs
Market Capitalization
$137.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.57

Graphite Bio MarketRank™ Forecast

Analyst Rating
Hold
1.89 Rating Score
Upside/​Downside
131.0% Upside
$5.43 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of Graphite Bio in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.39) to ($1.17) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

440th out of 983 stocks

Biological Products, Except Diagnostic Industry

74th out of 163 stocks

See Top Rated MarketRank™ Stocks Here

GRPH stock logo

About Graphite Bio (NASDAQ:GRPH) Stock

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Receive GRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter.

GRPH Stock News Headlines

March 22, 2023 | americanbankingnews.com
Graphite Bio (NASDAQ:GRPH) Issues Earnings Results
March 22, 2023 | americanbankingnews.com
Graphite Bio (NASDAQ:GRPH) Posts Earnings Results, Beats Estimates By $0.05 EPS
March 22, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
March 21, 2023 | markets.businessinsider.com
BTIG Sticks to Its Hold Rating for Graphite Bio (GRPH)
March 20, 2023 | finance.yahoo.com
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
March 18, 2023 | americanbankingnews.com
Contrasting Inhibrx (NASDAQ:INBX) & Graphite Bio (NASDAQ:GRPH)
March 18, 2023 | americanbankingnews.com
Reviewing Inhibrx (NASDAQ:INBX) and Graphite Bio (NASDAQ:GRPH)
March 17, 2023 | americanbankingnews.com
Graphite Bio, Inc. (NASDAQ:GRPH) Given Average Recommendation of "Hold" by Brokerages
March 22, 2023 | Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
February 24, 2023 | marketwatch.com
Graphite Bio to Reduce Workforce by 50%, Explores Strategic Alternatives
February 24, 2023 | benzinga.com
Graphite Bio shares are trading higher after the company announced a process to explore strategic alternatives.
February 23, 2023 | finance.yahoo.com
Sickle-cell gene therapy developer stops program, cuts half of staff
February 23, 2023 | msn.com
Graphite Bio adds 10%, most in eight months even as downgrades pile up
February 22, 2023 | finance.yahoo.com
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
January 25, 2023 | markets.businessinsider.com
Expert Ratings for Graphite Bio
January 10, 2023 | finance.yahoo.com
Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround
January 9, 2023 | msn.com
Looking Into Graphite Bio's Recent Short Interest
January 5, 2023 | finance.yahoo.com
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
January 5, 2023 | finance.yahoo.com
Graphite Bio pauses early-stage blood disease therapy trial
December 12, 2022 | barrons.com
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64(th) ASH Annual Meeting
December 11, 2022 | finance.yahoo.com
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
December 9, 2022 | seekingalpha.com
Graphite Bio: Underfollowed Gene Editing Play At An Attractive Valuation
November 21, 2022 | finance.yahoo.com
Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
November 9, 2022 | finance.yahoo.com
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
November 5, 2022 | barrons.com
Graphite Bio Announces Abstracts Accepted for Upcoming 64(th) ASH Annual Meeting and Exposition
November 3, 2022 | finance.yahoo.com
Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition
October 16, 2022 | finance.yahoo.com
Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation
See More Headlines
Receive GRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter.

GRPH Company Calendar

Last Earnings
3/20/2023
Today
3/22/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRPH
CUSIP
N/A
CIK
1815776
Web
www.graphitebio.com
Phone
650-484-0886
Fax
N/A
Employees
69
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.43
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+139.1%
Consensus Rating
Hold
Rating Score (0-4)
1.89
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.76)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-70,760,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-27.25%
Return on Assets
-25.97%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
22.07
Quick Ratio
22.07

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.61 per share
Price / Book
0.35

Miscellaneous

Outstanding Shares
58,150,000
Free Float
35,793,000
Market Cap
$135.49 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Joshua Lehrer-Graiwer FACC (Age 48)
    M.D., Pres, CEO & Director
    Comp: $724.58k
  • Dr. Matthew Porteus M.D. (Age 57)
    Ph.D., Academic Founder & Director
    Comp: $90.77k
  • Dr. Maria Grazia Roncarolo M.D. (Age 68)
    Ph.D., Academic Founder & Chair of Scientific Advisory Board
    Comp: $70k
  • Mr. Philip P. Gutry (Age 49)
    Chief Bus. Officer
    Comp: $541.33k
  • Dr. Daniel Dever Ph.D.
    Co-Founder & Head of Discovery Research
  • Ms. Alethia Rene Young (Age 43)
    Chief Financial Officer
  • Dr. Christine Garrett P.M.P. (Age 51)
    Ph.D., Chief of Staff & Sr. VP of Operations
  • Mr. Jerry Cacia (Age 55)
    Chief Technical Officer
  • Dr. Jane Grogan Ph.D. (Age 54)
    Chief Scientific Officer
  • Stephanie Yao
    VP of Communications & Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













GRPH Stock - Frequently Asked Questions

Should I buy or sell Graphite Bio stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Graphite Bio in the last year. There are currently 1 sell rating and 8 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GRPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRPH, but not buy additional shares or sell existing shares.
View GRPH analyst ratings or view top-rated stocks.

What is Graphite Bio's stock price forecast for 2023?

9 analysts have issued twelve-month price objectives for Graphite Bio's shares. Their GRPH share price forecasts range from $2.00 to $18.00. On average, they predict the company's stock price to reach $5.43 in the next twelve months. This suggests a possible upside of 133.0% from the stock's current price.
View analysts price targets for GRPH or view top-rated stocks among Wall Street analysts.

How have GRPH shares performed in 2023?

Graphite Bio's stock was trading at $3.32 at the beginning of the year. Since then, GRPH stock has decreased by 29.8% and is now trading at $2.33.
View the best growth stocks for 2023 here.

When is Graphite Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our GRPH earnings forecast.

How were Graphite Bio's earnings last quarter?

Graphite Bio, Inc. (NASDAQ:GRPH) announced its quarterly earnings results on Monday, March, 20th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.05.

When did Graphite Bio IPO?

(GRPH) raised $224 million in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 14,000,000 shares at a price of $15.00-$17.00 per share.

What is Graphite Bio's stock symbol?

Graphite Bio trades on the NASDAQ under the ticker symbol "GRPH."

Who are Graphite Bio's major shareholders?

Graphite Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (9.82%), Privium Fund Management UK Ltd (1.05%), Board of Trustees of The Leland Stanford Junior University (0.79%), Renaissance Technologies LLC (0.57%), Geode Capital Management LLC (0.42%) and GSA Capital Partners LLP (0.37%). Insiders that own company stock include Biocapital LP Samsara and Phil Gutry.
View institutional ownership trends.

How do I buy shares of Graphite Bio?

Shares of GRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Graphite Bio's stock price today?

One share of GRPH stock can currently be purchased for approximately $2.33.

How much money does Graphite Bio make?

Graphite Bio (NASDAQ:GRPH) has a market capitalization of $135.49 million. The company earns $-70,760,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

How can I contact Graphite Bio?

The official website for the company is www.graphitebio.com. The company can be reached via phone at 650-484-0886 or via email at ir@graphitebio.com.

This page (NASDAQ:GRPH) was last updated on 3/22/2023 by MarketBeat.com Staff